| P50 | author | W. Mark Saltzman | Q23092145 |
| | William Chang | Q55278846 |
| P2093 | author name string | Jordan S Pober | |
| | Jillian W Andrejecsk | |
| P2860 | cites work | Covalently conjugated VEGF--fibrin matrices for endothelialization | Q73965515 |
| | Eotaxin (CCL11) induces in vivo angiogenic responses by human CCR3+ endothelial cells | Q73966728 |
| | Induction of angiogenesis by implantation of encapsulated primary myoblasts expressing vascular endothelial growth factor | Q74210294 |
| | Polymeric system for dual growth factor delivery | Q77106419 |
| | Expression of CCR2 by endothelial cells : implications for MCP-1 mediated wound injury repair and In vivo inflammatory activation of endothelium | Q78233810 |
| | The role of fibroblast growth factors in vascular development | Q78384186 |
| | Angiogenic effects of sequential release of VEGF-A165 and PDGF-BB with alginate hydrogels after myocardial infarction | Q80269916 |
| | Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A | Q80894668 |
| | Membrane type 1-matrix metalloproteinase is regulated by chemokines monocyte-chemoattractant protein-1/ccl2 and interleukin-8/CXCL8 in endothelial cells during angiogenesis | Q80937048 |
| | Myocardial homing and neovascularization by human bone marrow angioblasts is regulated by IL-8/Gro CXC chemokines | Q82385171 |
| | Nanocomposite degradable hydrogels: demonstration of remote controlled degradation and drug release | Q83133869 |
| | The influence of the sequential delivery of angiogenic factors from affinity-binding alginate scaffolds on vascularization | Q83202158 |
| | Delivery of fibroblast growth factor 2 enhances the viability of cord blood-derived mesenchymal stem cells transplanted to ischemic limbs | Q83572896 |
| | Injectable system for spatio-temporally controlled delivery of hypoxia-induced angiogenic signalling | Q84224922 |
| | Novel vascular endothelial growth factor gene delivery system-manipulated mesenchymal stem cells repair infarcted myocardium | Q84446896 |
| | Sustained delivery of VEGF from designer self-assembling peptides improves cardiac function after myocardial infarction | Q84456355 |
| | A stromal cell-derived factor-1 releasing matrix enhances the progenitor cell response and blood vessel growth in ischaemic skeletal muscle | Q84890951 |
| | Molecular cloning and expression of human hepatocyte growth factor | Q24305558 |
| | Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis | Q24610450 |
| | Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2 | Q28187887 |
| | Integrins and the activation of latent transforming growth factor beta1 - an intimate relationship | Q28272771 |
| | Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury | Q28286412 |
| | Vascular endothelial growth factor is a secreted angiogenic mitogen | Q28646475 |
| | Molecular regulation of vessel maturation | Q29614540 |
| | Pericyte Loss and Microaneurysm Formation in PDGF-B-Deficient Mice | Q29615196 |
| | VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia | Q29617501 |
| | Chemokines as mediators of neovascularization | Q30438032 |
| | A macroporous hydrogel for the coculture of neural progenitor and endothelial cells to form functional vascular networks in vivo. | Q30477019 |
| | The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity | Q33181330 |
| | Sustained release of multiple growth factors from injectable polymeric system as a novel therapeutic approach towards angiogenesis | Q33517020 |
| | Tissue-engineered vascular grafts transform into mature blood vessels via an inflammation-mediated process of vascular remodeling | Q33537670 |
| | Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development | Q33633524 |
| | Synergistic angiogenic effect of codelivering fibroblast growth factor 2 and granulocyte-colony stimulating factor from fibrin scaffolds and bone marrow transplantation in critical limb ischemia | Q33659382 |
| | Dual delivery of VEGF and MCP-1 to support endothelial cell transplantation for therapeutic vascularization | Q33684402 |
| | Induction, differentiation, and remodeling of blood vessels after transplantation of Bcl-2-transduced endothelial cells. | Q33722822 |
| | Functions of mammalian Smad genes as revealed by targeted gene disruption in mice | Q33857584 |
| | An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes | Q33862469 |
| | Explant outgrowth, propagation and characterization of human pericytes | Q34084070 |
| | Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model | Q34125421 |
| | Endothelial-pericyte interactions in angiogenesis. | Q34217484 |
| | Tracheobronchial transplantation with a stem-cell-seeded bioartificial nanocomposite: a proof-of-concept study. | Q34236181 |
| | MCP-1 promotes mural cell recruitment during angiogenesis in the aortic ring model | Q34257029 |
| | Engineering vascularized skeletal muscle tissue | Q34427542 |
| | Vascular endothelial growth factor: basic science and clinical progress | Q34549887 |
| | Clinical transplantation of a tissue-engineered airway. | Q34885214 |
| | Stimulus-responsive "smart" hydrogels as novel drug delivery systems | Q34961959 |
| | Controlled release of chitosan/heparin nanoparticle-delivered VEGF enhances regeneration of decellularized tissue-engineered scaffolds | Q35071607 |
| | Angiogenic and angiostatic factors in the molecular control of angiogenesis. | Q35191425 |
| | In vivo formation of complex microvessels lined by human endothelial cells in an immunodeficient mouse | Q35199743 |
| | FGF-dependent regulation of VEGF receptor 2 expression in mice | Q35572401 |
| | New alginate microcapsule system for angiogenic protein delivery and immunoisolation of islets for transplantation in the rat omentum pouch. | Q35622019 |
| | Global expression profiling of fibroblast responses to transforming growth factor-beta1 reveals the induction of inhibitor of differentiation-1 and provides evidence of smooth muscle cell phenotypic switching | Q35749008 |
| | Fibroblast growth factor-2 facilitates rapid anastomosis formation between bioengineered human vascular networks and living vasculature. | Q35988758 |
| | Tissue-engineered vascular grafts for use in the treatment of congenital heart disease: from the bench to the clinic and back again | Q36062796 |
| | Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis | Q36111400 |
| | PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors | Q36234340 |
| | Signaling and functions of angiopoietin-1 in vascular protection. | Q36462707 |
| | Engineering of multifunctional gels integrating highly efficient growth factor delivery with endothelial cell transplantation | Q36804985 |
| | Matrices and scaffolds for drug delivery in vascular tissue engineering | Q36826700 |
| | Guided bone regeneration using injectable vascular endothelial growth factor delivery gel | Q36892937 |
| | Fibroblast growth factor regulation of neovascularization | Q37129668 |
| | Tie2 is tied at the cell-cell contacts and to extracellular matrix by angiopoietin-1 | Q37184780 |
| | Clinical application of scaffolds for cartilage tissue engineering | Q37330102 |
| | PDGF mediates cardiac microvascular communication | Q37384601 |
| | The role of the Angiopoietins in vascular morphogenesis. | Q37486191 |
| | Angiopoietin-1/Tie2 receptor signaling in vascular quiescence and angiogenesis | Q37669888 |
| | TGF-β in wound healing: a review | Q37790263 |
| | Stromal cell-derived factor-1 (SDF-1): homing factor for engineered regenerative medicine. | Q37827159 |
| | The role of pericytes in angiogenesis | Q37895203 |
| | Tissue engineering for the oncologic urinary bladder. | Q38036123 |
| | Human basic fibroblast growth factor fused with Kringle4 peptide binds to a fibrin scaffold and enhances angiogenesis | Q38287763 |
| | CCL2 regulates angiogenesis via activation of Ets-1 transcription factor | Q38310933 |
| | Instructive nanofiber scaffolds with VEGF create a microenvironment for arteriogenesis and cardiac repair. | Q39572280 |
| | Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells. | Q39740070 |
| | Collagen nerve conduits releasing the neurotrophic factors GDNF and NGF. | Q39758911 |
| | Site-specific delivery of acidic fibroblast growth factor stimulates angiogenic and osteogenic responses in vivo | Q40514229 |
| | Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis | Q40553670 |
| | Tissue engineering: creation of long-lasting blood vessels | Q40579851 |
| | Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression | Q40868885 |
| | Cxc chemokine receptor expression on human endothelial cells | Q40930195 |
| | Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity | Q41489951 |
| | VEGF gene delivery to myocardium: deleterious effects of unregulated expression | Q41757138 |
| | Magnetically triggered nanocomposite membranes: a versatile platform for triggered drug release. | Q42133573 |
| | CCL16 activates an angiogenic program in vascular endothelial cells. | Q42447162 |
| | Induction of angiogenesis in a mouse model using engineered transcription factors | Q42808653 |
| | Human aortic smooth muscle cells promote arteriole formation by coengrafted endothelial cells. | Q43131926 |
| | Local delivery of basic fibroblast growth factor increases both angiogenesis and engraftment of hepatocytes in tissue-engineered polymer devices | Q44013376 |
| | Modulation of angiogenic potential of collagen matrices by covalent incorporation of heparin and loading with vascular endothelial growth factor | Q45180195 |
| | Production and in vivo effects of chemokines CXCL1-3/KC and CCL2/JE in a model of inflammatory angiogenesis in mice. | Q45186058 |
| | Sustained release of VEGF through PLGA microparticles improves vasculogenesis and tissue remodeling in an acute myocardial ischemia-reperfusion model. | Q45323473 |
| | Transplantation of Sendai viral angiopoietin-1-modified mesenchymal stem cells for ischemic limb disease. | Q45858966 |
| | Loading of VEGF to the heparin cross-linked demineralized bone matrix improves vascularization of the scaffold. | Q45919200 |
| | Localized arteriole formation directly adjacent to the site of VEGF-induced angiogenesis in muscle. | Q45981429 |
| | In vitro and in vivo release of vascular endothelial growth factor from gelatin microparticles and biodegradable composite scaffolds. | Q46458076 |
| | Vascular endothelial growth factor-releasing scaffolds enhance vascularization and engraftment of hepatocytes transplanted on liver lobes. | Q46584283 |
| | Long-term and zero-order release of basic fibroblast growth factor from heparin-conjugated poly(L-lactide-co-glycolide) nanospheres and fibrin gel. | Q46690652 |
| | Robust functional vascular network formation in vivo by cooperation of adipose progenitor and endothelial cells. | Q47795916 |
| | The role of actively released fibrin-conjugated VEGF for VEGF receptor 2 gene activation and the enhancement of angiogenesis | Q48011091 |
| | Angiogenesis-like activity of endothelial cells co-cultured with VEGF-producing smooth muscle cells. | Q50736145 |
| | Transplantation of an allogeneic vein bioengineered with autologous stem cells: a proof-of-concept study. | Q50752744 |
| | Engineered fibrin matrices for functional display of cell membrane-bound growth factor-like activities: study of angiogenic signaling by ephrin-B2. | Q51022950 |
| | Temporally regulated delivery of VEGF in vitro and in vivo. | Q51175851 |
| | Dose-finding study of fibrin gel-immobilized vascular endothelial growth factor 165 and basic fibroblast growth factor in the arteriovenous loop rat model. | Q51765126 |
| | The effect of the delivery of vascular endothelial growth factor and bone morphogenic protein-2 to osteoprogenitor cell populations on bone formation. | Q51922236 |
| | Preparation and characterization of collagen microspheres for sustained release of VEGF. | Q53335799 |
| | Active blood vessel formation in the ischemic hindlimb mouse model using a microsphere/hydrogel combination system. | Q53477371 |
| | Arteriogenic therapy by intramyocardial sustained delivery of a novel growth factor combination prevents chronic heart failure. | Q54569110 |
| | Hepatocyte growth factor induces a proangiogenic phenotype and mobilizes endothelial progenitor cells by activating Nox2. | Q54635450 |
| | Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1 | Q61773870 |
| | The effects of platelet-derived growth factor in cultured microvessel endothelial cells | Q69962768 |
| | The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis | Q73139585 |
| | Development and in vitro characterization of vascular endothelial growth factor (VEGF)-loaded poly(DL-lactic-co-glycolic acid)/poly(ethylene glycol) microspheres using a solid encapsulation/single emulsion/solvent extraction technique | Q73953544 |
| P433 | issue | 2 | |
| P304 | page(s) | 75-88 | |
| P577 | publication date | 2015-04-01 | |
| P1433 | published in | Drug delivery and translational research | Q27723621 |
| P1476 | title | Controlled protein delivery in the generation of microvascular networks | |
| P478 | volume | 5 | |